BL-8040 Addition to Consolidation Therapy in AML Patients (BLAST)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02502968 |
Recruitment Status : Unknown
Verified September 2015 by Dr. Petra Tschanter, Martin-Luther-Universität Halle-Wittenberg.
Recruitment status was: Recruiting
First Posted : July 20, 2015
Last Update Posted : September 21, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acute Myeloid Leukemia | Drug: Cytarabine Drug: BL-8040 Drug: Placebo (for BL-8040) | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 194 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Double- Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of BL-8040 Addition to Consolidation Therapy in AML Patients |
Study Start Date : | September 2015 |
Estimated Primary Completion Date : | July 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: Cytarabine & BL8040
Subjects ≥60 years: cytarabine 1g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 2 cycles and BL-8040 (1.25 mg/kg) subcutaneously on days 1 to 5 of each cycle Subjects <60 years: cytarabine 3g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 3 cycles and BL-8040 (1.25 mg/kg) subcutaneously on days 1 to 5 of each cycle |
Drug: Cytarabine Drug: BL-8040 |
Active Comparator: Cytarabine & Placebo
Subjects ≥60 years: cytarabine 1g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 2 cycles and Placebo (for BL-8040) subcutaneously on days 1 to 5 of each cycle Subjects <60 years: cytarabine 3g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 3 cycles and Placebo (for BL-8040) subcutaneously on days 1 to 5 of each cycle |
Drug: Cytarabine Drug: Placebo (for BL-8040) Powder for solution for injection manufactured to mimic BL-8040 |
- Relapse Free Survival time [ Time Frame: 18 months ]Relapse is defined as recurrence of leukemic blasts (more than 5%) in the bone marrow after confirmed complete remission
- Overall Survival [ Time Frame: 18 months ]
- Time to relapse [ Time Frame: 18 months ]
- Relapse free survival [ Time Frame: 6, 9, 12 and 18 months ]
- Relapse [ Time Frame: 6, 9, 12 and 18 months ]Defined as recurrence of leukemic blasts (more than 5%) in the bone marrow after confirmed complete remission
- Minimal residual disease [ Time Frame: 6, 9, 12 and 18 months ]Immunophenotypic characterization of human bone marrow cells will be done to determine MRD
- Toxicity [ Time Frame: enitire study course until 18 months ]Number and CTC grade of all adverse events related to study treatment analyzed in an descriptive way

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically or morphologically confirmed diagnosis of AML except for AML M3 (acute promyelocytic leukemia)
- AML who achieved complete remission (CR), including CRi and CRp after a maximum number of 2 cycles of induction chemotherapy.
- AML subjects younger than 60 years at the time of diagnosis with intermediate or high-risk cytogenetics
- ECOG performance status ≤2
- Laboratory values as follows (at time of randomization): WBC < 30.000/μl and > 1000/μl, Platelets count > 70.000/μl, Creatinine < 1.0 mg/dl. If creatinine is between 1.0mg/dl and 1.3mg/dl, creatinine clearance should be > 30ml/min as calculated using the Cockroft-Gault formula
- Women of child-bearing potential must practice an acceptable method of birth control until 6 month after the last dose of treatment. Female subjects who are lactating must discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for 14 days following the last dose of study drug.
- Male with a female partner of childbearing potential using a barrier method of contraception
- Written informed consent
- Subject is able and willing to comply with the requirements of the protocol.
Exclusion Criteria:
- Relapsed or refractory AML
- Start of induction cycle > 90 days before randomization.
- Subjects who have received >2 cycles of induction chemotherapy for AML therapy.
- Subjects younger than 60 years at the time of diagnosis with favorable cytogenetics (t(8;21) or inv(16) or t(16;16) or t(15;17)) or the confirmed presence of the resulting fusion protein AML1-ETO, CBFB-MYH11 or PML-RARA.
- Subjects for which allogeneic HSCT is planned in CR1.
- Planned further maintenance therapy after the end of the protocol defined consolidation therapy.
- Known allergic or hypersensitivity to BL8040- or cytarabine or to any of the test compounds, materials
- Use of investigational device or agents within 2 weeks or less than 5 half lifes for each investigational product /device at the time of enrolment. Registry studies are permissible.
- Abnormal liver function tests: Serum AST/ GOT or ALT/ GPT > 3x upper limit of normal (ULN), Serum bilirubin: Total bilirubin > 2.0mg/dl, conjugated bilirubin > 0.8mg/dl
- O2 saturation < 92% (on room air)
- Concurrent, uncontrolled medical condition, laboratory abnormality, or psychiatric illness which could place the subject at unacceptable risk
- Another malignancy within 3 years of enrolment, except in situ malignancy, or low-risk prostate, skin or cervical cancer after curative therapy. History of other cancer that according to the Investigator might confound the assessment of the endpoints of the study.
- A co-morbid condition which, in the view of the Investigators, renders the subject at high risk from treatment complications.
- History of any or more of the following cardiovascular conditions: cardiac angioplasty (within 6 months) or stenting (within 6 months) and/or myocardial infarction (MI) (within 6 months) or cerebro-vascular event within the past 6 months, unstable angina, vascular disease, class III or IV, congestive heart failure (as defined by the New York Heart Association (NYHA))
- Known central nervous system disease that may jeopardize the subject's study participation according to the investigator judgement
- Active, uncontrolled infection.
- Prior clinically significant grade 3-4 non-hematological toxicity to high-dose cytarabine or grade ≥ 2 of neurological toxicity
- Positive serology for HIV, active Hepatitis C and Hepatitis B (HBsAG pos.) at baseline
- Left ventricular ejection fraction (LVEF) of <40% by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO) at baseline
- Subjects with psychological, psychiatric, neurological, familial, sociological, or geographical conditions that do not permit compliance with the protocol

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02502968
Contact: Simone Kowoll, MSc | +49-345-5574908 | blast@kks-halle.de |
Germany | |
Univeritätsklinikum Halle, Klinik Innere Medizin 4 | Recruiting |
Halle, Germany, 06120 | |
Contact: Carsten Müller-Tidow |
Principal Investigator: | Carsten Müller-Tidow, MD | University Hospital Halle, Germany |
Responsible Party: | Dr. Petra Tschanter, Dr. med., Martin-Luther-Universität Halle-Wittenberg |
ClinicalTrials.gov Identifier: | NCT02502968 History of Changes |
Other Study ID Numbers: |
UKH062014 |
First Posted: | July 20, 2015 Key Record Dates |
Last Update Posted: | September 21, 2015 |
Last Verified: | September 2015 |
Cytarabine Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |
Antiviral Agents Anti-Infective Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |